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Abstract
Background: Sertoli - Leydig cell tumors (SLCTs) are sex-cord stromal tumors that account less than 0.5 % of primary
ovarian neoplasms. They are mostly benign and occur in reproductive age women. Variants with heterologous
mesenchymal elements are exceptionaly rare. The usual presentation of SLCTs is with signs of androgen excess as
majority of them produce androgens.
Case presentation: We present a case of a SLCT occurring in a 70 year old woman. Her presenting complaint was
abdominal distension and pain. She had no signs of androgen or estrogen excess. Transvaginal ultrasound (TVUS) and
CT scan showed a multilocular adnexal tumor and level of CA 125 was raised. A complete cytoreduction was achieved
with surgical procedure. Histopathological examination revealed moderately differentiated SLCT with retiform areas
and owergrowth of heterologous component in form of embrional rhabdomyosarcoma (RMS). She returned 7 months
after the surgery with a large abdominal mass, ascites, right- sided hydronephrosis and massive pulmonary embolism.
Due to the widespread disease and her poor general condition, she received only palliative care. She died 15 days after
the admission. No autopsy was performed.
Conclusions: Due to the rarity of SLCTs, especially those with retiform areas and heterologous elements, their
management remains challenging. There is no firm evidence that adjuvant chemotherapy is effective in improving
survival in SLCTs with malignant heterologous elements. Further studies with a higher number of cases and a longer
follow-up are needed to better predicting the prognosis and determine the role of chemotherapy in such cases.
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Background
Sertoli – Leydig cell tumors (SLCT) are sex cord-stromal
tumors that account for less than 0.5 % of primary ovarian
neoplasms [1]. Because of their scarcity SLCT represent a
challenge in diagnosis and management.
The vast majority of SLCT (90 %) occur in the reproduct-
ive age and the rest before menarche or after menopause
[2]. They are usually unilateral and confined to the ovary at
the time of diagnosis. Approximately 80 % of SLCT are
hormonally active with elevated serum testosterone and
androstenedione levels and one third of these tumors is dis-
covered due to the clinical signs and symptoms of excess
androgen production (virilization, voice deepening, male
pattern baldness, amenorrhea, clitoromegaly) [3]. Occasio-
naly patients have estrogenic manifestations (menometror-
rhagia, postmenopausal bleeding) [4]. Abdominal mass,
pain and distension and ascites are the clinical presen-
tations in approximately 50 % of these tumors [5].
According to the WHO classification [6] SLCTs are sub-
divided into well, moderately and poorly differentiated
tumors depending on the degree of tubular differentiation
of the Sertoli cell component (with poorly differentiated tu-
mors having the least tubular differentiation). Heterologous
mesenchymal or epithelial elements are found in up to
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20 % of SLCTs and they occur only in moderately and
poorly differentiated tumors or tumors with retiform pat-
tern [7]. The prognosis depends on the patient’s age, stage
of the tumor and the degree of differentiation with the
presence of heterologous elements or retiform pattern
being a bad prognostic feature [1].
We report an extremely rare case of moderately differ-
entiated retiform SLCT with extensive owergrowth of
heterologous rhabdomyosarcomatous (RMS) component
occurring in a postmenopausal patient.
Case presentation
A 70 – year-old, para 2, was referred to our centre with
severe right-sided lower abdominal pain that started a
few days prior to her visit. She had gained 4 kg, noticed
abdominal distension and occasional dull right-sided
lower abdominal pain in the 2 months prior to admis-
sion. She was otherwise healthy, without any regular
medical therapy. She had two vaginal deliveries and her
last period was at the age of 46. She had no significant
gynecological history. Speculum examination revealed
normal-looking vagina and cervix. Upon bimanual
palpation a large, smooth and mobile tumor formation,
extending from the top of a normal sized uterus up to
the umbilicus, was felt. Transvaginal ultrasound (TVUS)
examination showed a large, well-vascularized, pelvic
mass with solid and cystic components above the uterus
and a small amount of ascites in the pouch of Douglas.
Contrast enhanced computed tomography (CT) scan of
the abdomen showed a well circumscribed, multilocular,
complex tumor formation measuring 19 × 12 × 21 cm
that appeared to originate from adnexal area, and a
thickened, 15 mm, non-homogenous endometrium.
Chest X ray showed no evidence of pulmonary nodules.
Laboratory tests showed increased serum level of CA-
125 at 135.5 U/ml whereas CA 15–3, CA 19–9, CEA
were within the normal range. Serum testosterone levels
were not determined as there were no signs of androgen
excess and they are not a part of a routine pre-operative
evaluation at our clinic. Subsequently, exploratory lapar-
otomy was performed. Right ovary with the tumor was
removed and sent for intra-operative frozen section
evaluation, which revealed features of ovarian malig-
nancy. Hysterectomy with left salpingo-oopherectomy,
appendectomy, omentectomy, peritoneal biopsies, pelvic
and para-aortic lymphadenectomy were therefore per-
formed and there was no macroscopic disease remnant
at the end of the procedure.
On gross examination the tumor was cystic and solid
with extensive areas of necrosis and hemorrhage.
Microscopically, most of the tumor consisted of a high
grade spindle cell sarcoma with numerous mitoses, areas of
necrosis and focal cells with ample eosinophilic cytoplasm,
consistent with rhabdomyoblasts. Immunohistochemically,
this component was diffusely positive for desmin and myo-
genin. At the periphery of this mass the tumor was com-
posed of cords and nests of cells with clear cytoplasm
intimately admixed with cells with more abundant eosino-
philic cytoplasm; some cystically dilated structures were
also present. Immunohistochemically, both types of cells
were diffusely positive for inhibin and calretinin. A diag-
nosis of a Sertoli-Leydig cell tumor with retiform areas
and heterologous rhabdomyosarcomatous component
overgrowth was rendered. Morphological and immunohis-
tochemical characteristics of the tumor are depicted in
Figs. 1a-d and 2a-d.
The tumor was staged IA and we decided not to
administer postoperative chemo- or radiotherapy.
At her first post-operative check up, 8 weeks post pro-
cedure, clinical exam and TVUS showed no signs of dis-
ease recurrence and the patient was well. She returned
to our clinic 7 months after the procedure with abdom-
inal pain, ascites and a large palpable abdominal mass.
She lost 5 kg in 1 month and noticed leg swelling
2 weeks before the admission. CT scan showed a large
tumor mass extending from the pelvis measuring 21 ×
16 × 20 cm (Fig. 3). Additional tumor masses measuring
10 × 15 × 15 cm below the left hemi-diafragm reaching
to the spleen and a mass measuring 3 × 4 × 5.6 cm at the
splenic hilum were seen. Serum testosterone level was
slightly elevated at 1.7 nmol/L. Furthermore, CT scan
showed approximately 2 l of ascites and a massive
pulmonary embolism with pulmonary infarction and
right-sided heart failure. The patient was treated with
therapeutic dosage of low-molecular weight heparin and
received several blood transfusions. Nephrostomy tube
was inserted because of the right-sided hydronephrosis.
Due to the widespread of the disease with poor progno-
sis and patient’s poor general condition, we decided not
to perform the surgical procedure. She received paliative
care. She died on the fifteenth day after the admission.
Her family resigned from an autopsy.
Discussion
SLCTs are mixed sex cord-stromal tumors composed of
variable proportions of Sertoli cells, Leydig cells and in
the case of moderately and poorly differentiated neo-
plasms primitive gonadal stroma and sometimes heterol-
ogous elements. When the tumor shows pattern wich
can vary from anastomosing, slit-like spaces resembling
rete testis to areas of papillary or multicystic pattern
with sieve-like spaces, the term retiform SLCT is used.
Retiform pattern is found in approximately 15 % of SLCTs
[8]. Retiform SLCTs occur at a younger age (mean age
15 years) and mostly present with a large abdominal tumor
and pain rather than virilization [9]. Approximately 20 %
of SLCT contain heterologous elements [1, 2, 7]. Heterol-
ogous elements include epihelial and/or mesenchymal
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tissue and tumors arising from these tissues (mucinous
gastro-intestinal epithelium, hepatocytes, skeletal muscle,
cartilage, adipose tissue, mucinous carcinoma, carcinoid,
rhabdomiosarcoma, neuroblastoma) [6]. The most com-
mon heterologous element is mucinous epithelium of
enteric type, others are rare [1, 2]. Five percent of SLCTs
contain mesenchymal elements [10]. Both retiform and
heterologous elements are only found in moderately and
poorly differentiated SLCTs.
Little is known about the pathogenesis of ovarian
SLCT however, germ-line mutations in the microRNA
processing gene DICER1 have been shown to be related
with the development of benign tumors that are suscep-
tible to malignant transformation [11]. These tumors
Fig. 2 Immunohistochemistrty revealed diffuse strong positivity for inhibin (a) and calretinin (b) in the Sertoli-Leydig cell component and for desmin
(c) and myogenin (d) in the sarcomatous component (x200)
Fig. 1 a Microscopically, the tumor was composed of a Sertoli-Leydig cell and rhabdomyosarcomatous component (x100). b In some areas, dilated
cystic structures were present (x100). c Sertoli-Leydig cell component composed of cords and islands of Sertoli cells surrounded by Leydig cells with
more abundant eosinophilic cytoplasm (x200). d Sarcomatous component with many larger cells with abundant eosinophilic cytoplasm suggesting
rhabdomyoblastic differentiation (x200)
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include ovarian SLCT, multinodular goiter, multilocular
cystic nephroma and pleuropulmonary blastoma [12–14].
Heravi-Moussavi et al. [12] report a 60 % prevalence of
DICER1 mutations in SLCT. Similarly, in the study of
Conlon et al. [15] DICER1 mutations were present in 63 %
of SLCT. They also report that there is no association
between DICER1 mutation and tumor differentiation as
mutations in poorly differentiated and moderately differ-
entiated SLCT were found to have similar frequencies. It
has been established, that reduced expression of DICER1
is associated with a poor cancer outcome [16]. The exact
mechanism underlying tumorigenesis associated with
DICER1 mutations remains to be determined, however.
The prognosis of SLCTs is overall favorable and de-
pends on the stage and histological grade of the tumor
and the age of the patient. The overall 5- year survival
rate for stage I is 95 % and for stages III and IV almost
0 %. Histological grade also correlates with prognosis as
a study of 207 cases of SLCTs reported that well-
differentiated tumors behaved benign whereas 11 % of
moderately differentiated, 19 % of those with heterol-
ogous elements and 59 % of poorly differentiated were
clinically malignant [1]. The presence of a retiform pat-
tern seems to have an adverse affect on the prognosis,
however, the malignant potential of this pattern remains
uncertain [9, 17]. Also, the presence of heterologous
mesenchymal elements appears to be associated with a
poor prognosis [18].
Because SLCTs are very rare, a standardized approach
for treatment has not been established yet. Unilateral
salpingo-oopherectomy seems to be sufficient in well-
differentiated unilateral SLCTs [19]. In cases of moder-
ately and poorly differentiated SLCTs and SLCTs with
heterologous elements hysterectomy, bilateral salpingo-
oopherectomy and staging (omentectomy, appendectomy
and pelvic lymphadenectomy) should be performed [20].
Maximal tumor debulking is recommended for SLCTs
with extra-ovarian spread. Adjuvant chemotherapy has
been suggested for cases of stage IB to IV, recurrent
SLCTs and poorly differentiated SLCTs with heterologous
elements [21] however, the value of adjuvant chemother-
apy has not yet been determined [22]. Grove et al. [23]
suggested that for moderately differentiated SLCTs with
heterologous elements, the percentage of sarcoma and its
cellular differentiation should be evaluated to decide
whether or not to use adjuvant chemotherapy. Their
patient had a moderately differentiated SLCT with RMS
elements and did not receive postoperative chemotherapy.
Despite that, she was disease free 4 years after the pro-
cedure. On the other hand, Prat et al. [18] suggested
that in cases of SLCTs with mesenchymal elements the
prognosis is as poor as in primary ovarian sarcomas
and thus adjuvant chemotherapy should be given for all
disease stages.
In our case, a moderately differentiated retiform SLCT
with retiform areas and overgrowth of the heterologous
RMS component occurred in a postmenopausal patient.
Two of the previously described cases of moderately
differentiated SLCTs with RMS elements occupying only
small parts of the tumor had a benign disease course
[23, 24]. In contrast, a case where the RMS component
almost overgrew the SLCT, had a malignant disease
course with recurrence 6 and 10 months post surgical
therapy [25]. The recurrent tumor was composed exclu-
sively of RMS elements. Brief summarization of cases of
SLCTs containing malignant heterologous mesenchymal
elements can be found in Table 1.
Our patient had a FIGO stage IA tumor at the time of
the surgical treatment and complete macroscopic cytore-
duction was achieved. Despite that, her disease recurred
in 7 months confirming the aggressive behavior of SLCT
containing RMS and/or retiform elements. We assume
that the recurrent tumor was mainly composed of RMS
elements due to the aggressive disease course and only
slightly elevated serum testosterone levels. The rapid
disease progression implies that the presence of RMS
and/or retiform component in primary SLCTs causes an
unfavorable disease course and that it is the heterol-
ogous component in the SLCTs that affects the progno-
sis and not the grade of the Sertoli – Leydig component
itself, as it has already been suggested [1]. However, the
incidence of moderately differentiated SLCTs with RMS
and SLCTs with retiform component is very low, and we
are not able to conclude how these elements truly affect
the disease course.
Ovarian RMS is an extremely rare tumor with a very
aggressive disease course and poor outcome regardless
Fig. 3 CT scan of recurrent tumor
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Table 1 Presentation of case reports of SLCTs containing malignant heterologous mesenchymal elements
Author Patient’s
age
Tumor size Laterality FIGO
stage






23 Right ovary IA Right SO / Immature skeletal muscle +
Immature cartilage +
Gastrointestinal epithelium








14 Left ovary IA Left SO Poor
differentitation
Cartilage in recurrent tumor Pelvis Radiotherapy Died after
9 months
















36 Right ovary IIB Right SO / Immature skeletal muscle +
Immature cartilage
Peritoneum / Died after
6 months
48 Left ovary IA TAH + Left SO / Immature skeletal muscle +
Immature cartilage
Not specified Not specified Not specified
20 Right ovary IIB Right SO +
Chemotherapy
/ Immature skeletal muscle Left ovary,
Douglas pouch










Biopsy / Immature skeletal muscle Not specified Not specified Not specified









22 6 cm Left ovary IA Left SO Moderate
differentitation






















6 and 10 months













of treatment [26]. It has been shown that optimal cytore-
duction to no gross residual disease improves survival
outcome in ovarian sarcomas [27, 28] and that age of
the patient and stage of the tumor are associated with
overall survival as well [28]. On the other hand, there
are no established guidelines whether patients with these
tumors should receive postoperative chemotherapy and
which regimen would be optimal. Bacalbasa et al. [29]
report of a case of primary ovarian RMS where the pa-
tient had a disease recurrence 2 months post surgical
treatment and died 4.5 months after the second surgical
intervention despite receiving adjuvant chemotherapy.
There are no specific guidelines about the follow-up of
patients after the surgery for SLCTs. In our case, the pa-
tient was followed up as patients with epithelial ovarian
cancer. Despite the fact that at her first post-operative
check-up, when clinical and TVUS examination were
performed, she was disease free, the recurrent tumor
6 months later was widespread and therefore considered
as not suitable for surgical treatment. Thus, we believe
that imaging examination with a higher specificity and
sensitivity should be used for detection of SLCTs recur-
rence. Recently, positron emission positron emission
tomography (PET) combined with computed tomog-
raphy (CT) has been proposed as an imaging modality
for early detection of recurrence of ovarian cancer [30].
Gu et al. [31] reports of a 93 % pooled specificity and
91 % pooled sensitivity of PET CT for detection of recur-
rence of ovarian cancer. It has not yet been established
however, whether it would have similar success detecting
SLCT recurrence. Furthermore, there are no guidelines
on when to start and how often to use PET-CT in
patient follow-up after the treatment.
Conclusion
Management of ovarian SLCTs with malignant disease
course is challenging due to the rarity of the disease and
lack of experience. It seems that overgrowth of the SLCTs
with RMS elements causes a very unfavorable disease
course. Further reports of individual cases as well as ran-
domized controlled studies are needed for establishment
of management guidelines and the role of adjuvant
chemotherapy in these tumors. At present, there is no
good evidence that postoperative adjuvant chemotherapy
is effective in preventing recurrence of malignant SLCTs.
Toxicity and the ability to complete the chemotherapy
regimen should be kept in mind when deciding about
application of toxic medications.
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